MedTrace Logo

Testing Gene PilotLX With Latinx Cancer Patients

NCT06476938 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2025-07-03

No results posted yet for this study

Summary

This is a randomized controlled trial designed to evaluate the efficacy of an electronic health decision support tool called Gene PilotLX to increase informed decision making regarding hereditary risk information from tumor genomic profiling (TGP) test among Latinx cancer patients recruited at four cancer centers.

Conditions

Interventions

OTHER

Gene PilotLX

eHealth decision making tool regarding tumor genomic profiling

Sponsors & Collaborators

  • Temple University

    collaborator OTHER

  • MD Anderson Cancer Center at Cooper

    collaborator OTHER

  • Herbert Irving Comprehensive Cancer Center

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Fox Chase Cancer Center

    lead OTHER

Principal Investigators

  • Michael J Hall, MD,MS · Fox Chase Cancer Center

  • Sarah B Bass, PhD, MPH · Temple University

  • Tracey A Revenson, PhD · Hunter College of City University of New York

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-30
Primary Completion
2027-05-01
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06476938 on ClinicalTrials.gov